ARCHIVES

NCI Cancer Education Program To Open To Innovative Ideas

This article is from The Cancer Letter archive.

Vol. 19 No. 14 | April 2, 1993

Download PDF Visit The Full Archive

Related Articles

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

December 26, 2014

Worker Health RFA May Finally Be Ready

August 26, 1988

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

May 6, 2005

NCI Agrees To Offer New Screening RFP In The Future

May 28, 1976

ODAC Recommends Ethyol, DaunoXome For FDA Approval

June 16, 1995

DCT Board Ok’s Grants Program For AIDS Malignancies, Contracts

October 23, 1992